Stabilization and enhancement of interleukin-2 in vitro bioactivity by new carriers: supramolecular biovectors
Identifieur interne : 000F12 ( Istex/Corpus ); précédent : 000F11; suivant : 000F13Stabilization and enhancement of interleukin-2 in vitro bioactivity by new carriers: supramolecular biovectors
Auteurs : Nathalie Castignolles ; Didier Betbeder ; Karim Ioualalen ; Otto Merten ; Claude Leclerc ; Daniel Samain ; Pierre PerrinSource :
- Vaccine [ 0264-410X ] ; 1994.
Abstract
Human recombinant interleukin-2 can be associated and released from supramolecular biovectors (SMBVs), consisting of particles made of polymerized polysaccharides. The particles are substituted with phosphate residues and contain bound lipid molecules (palmitic acid) buried near their surfaces. The association of IL-2 with SMBVs modifies its in vitro bioactivity. SMBVs prolong the growth of IL-2-dependent cells, enhance IL-2 proliferative activity and restore the activity of impaired IL-2. These properties mainly depend on the presence of lipids linked to the SMBV and on both the degree of acylation and the SMBV:IL-2 ratio. SMBVs are therefore good candidates for the stabilization and enhancement of the biological activity of IL-2.
Url:
DOI: 10.1016/0264-410X(94)90150-3
Links to Exploration step
ISTEX:5770F2CF470F8D8FABA7A3BDBE06220D55087837Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Stabilization and enhancement of interleukin-2 in vitro bioactivity by new carriers: supramolecular biovectors</title><author><name sortKey="Castignolles, Nathalie" sort="Castignolles, Nathalie" uniqKey="Castignolles N" first="Nathalie" last="Castignolles">Nathalie Castignolles</name><affiliation><mods:affiliation>Lyssavirus Laboratory, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France</mods:affiliation></affiliation></author><author><name sortKey="Betbeder, Didier" sort="Betbeder, Didier" uniqKey="Betbeder D" first="Didier" last="Betbeder">Didier Betbeder</name><affiliation><mods:affiliation>A&S Biovecteurs, Parc Technologique du Canal, 10 av. de l'Europe, 31520 Ramonville-St-Agne, France</mods:affiliation></affiliation></author><author><name sortKey="Ioualalen, Karim" sort="Ioualalen, Karim" uniqKey="Ioualalen K" first="Karim" last="Ioualalen">Karim Ioualalen</name><affiliation><mods:affiliation>A&S Biovecteurs, Parc Technologique du Canal, 10 av. de l'Europe, 31520 Ramonville-St-Agne, France</mods:affiliation></affiliation></author><author><name sortKey="Merten, Otto" sort="Merten, Otto" uniqKey="Merten O" first="Otto" last="Merten">Otto Merten</name><affiliation><mods:affiliation>Laboratoire de Technologie Cellulaire, Institut Pasteur, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Leclerc, Claude" sort="Leclerc, Claude" uniqKey="Leclerc C" first="Claude" last="Leclerc">Claude Leclerc</name><affiliation><mods:affiliation>Unité de Biologie des Régulations Immunitaires, Institut Pasteur, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Samain, Daniel" sort="Samain, Daniel" uniqKey="Samain D" first="Daniel" last="Samain">Daniel Samain</name><affiliation><mods:affiliation>A&S Biovecteurs, Parc Technologique du Canal, 10 av. de l'Europe, 31520 Ramonville-St-Agne, France</mods:affiliation></affiliation></author><author><name sortKey="Perrin, Pierre" sort="Perrin, Pierre" uniqKey="Perrin P" first="Pierre" last="Perrin">Pierre Perrin</name><affiliation><mods:affiliation>Lyssavirus Laboratory, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France</mods:affiliation></affiliation><affiliation><mods:affiliation>To whom correspondence should be addressed.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5770F2CF470F8D8FABA7A3BDBE06220D55087837</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1016/0264-410X(94)90150-3</idno><idno type="url">https://api.istex.fr/document/5770F2CF470F8D8FABA7A3BDBE06220D55087837/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000F12</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000F12</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Stabilization and enhancement of interleukin-2 in vitro bioactivity by new carriers: supramolecular biovectors</title><author><name sortKey="Castignolles, Nathalie" sort="Castignolles, Nathalie" uniqKey="Castignolles N" first="Nathalie" last="Castignolles">Nathalie Castignolles</name><affiliation><mods:affiliation>Lyssavirus Laboratory, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France</mods:affiliation></affiliation></author><author><name sortKey="Betbeder, Didier" sort="Betbeder, Didier" uniqKey="Betbeder D" first="Didier" last="Betbeder">Didier Betbeder</name><affiliation><mods:affiliation>A&S Biovecteurs, Parc Technologique du Canal, 10 av. de l'Europe, 31520 Ramonville-St-Agne, France</mods:affiliation></affiliation></author><author><name sortKey="Ioualalen, Karim" sort="Ioualalen, Karim" uniqKey="Ioualalen K" first="Karim" last="Ioualalen">Karim Ioualalen</name><affiliation><mods:affiliation>A&S Biovecteurs, Parc Technologique du Canal, 10 av. de l'Europe, 31520 Ramonville-St-Agne, France</mods:affiliation></affiliation></author><author><name sortKey="Merten, Otto" sort="Merten, Otto" uniqKey="Merten O" first="Otto" last="Merten">Otto Merten</name><affiliation><mods:affiliation>Laboratoire de Technologie Cellulaire, Institut Pasteur, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Leclerc, Claude" sort="Leclerc, Claude" uniqKey="Leclerc C" first="Claude" last="Leclerc">Claude Leclerc</name><affiliation><mods:affiliation>Unité de Biologie des Régulations Immunitaires, Institut Pasteur, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Samain, Daniel" sort="Samain, Daniel" uniqKey="Samain D" first="Daniel" last="Samain">Daniel Samain</name><affiliation><mods:affiliation>A&S Biovecteurs, Parc Technologique du Canal, 10 av. de l'Europe, 31520 Ramonville-St-Agne, France</mods:affiliation></affiliation></author><author><name sortKey="Perrin, Pierre" sort="Perrin, Pierre" uniqKey="Perrin P" first="Pierre" last="Perrin">Pierre Perrin</name><affiliation><mods:affiliation>Lyssavirus Laboratory, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France</mods:affiliation></affiliation><affiliation><mods:affiliation>To whom correspondence should be addressed.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1994">1994</date><biblScope unit="volume">12</biblScope><biblScope unit="issue">15</biblScope><biblScope unit="page" from="1413">1413</biblScope><biblScope unit="page" to="1418">1418</biblScope></imprint><idno type="ISSN">0264-410X</idno></series><idno type="istex">5770F2CF470F8D8FABA7A3BDBE06220D55087837</idno><idno type="DOI">10.1016/0264-410X(94)90150-3</idno><idno type="PII">0264-410X(94)90150-3</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Human recombinant interleukin-2 can be associated and released from supramolecular biovectors (SMBVs), consisting of particles made of polymerized polysaccharides. The particles are substituted with phosphate residues and contain bound lipid molecules (palmitic acid) buried near their surfaces. The association of IL-2 with SMBVs modifies its in vitro bioactivity. SMBVs prolong the growth of IL-2-dependent cells, enhance IL-2 proliferative activity and restore the activity of impaired IL-2. These properties mainly depend on the presence of lipids linked to the SMBV and on both the degree of acylation and the SMBV:IL-2 ratio. SMBVs are therefore good candidates for the stabilization and enhancement of the biological activity of IL-2.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Nathalie Castignolles</name><affiliations><json:string>Lyssavirus Laboratory, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France</json:string></affiliations></json:item><json:item><name>Didier Betbeder</name><affiliations><json:string>A&S Biovecteurs, Parc Technologique du Canal, 10 av. de l'Europe, 31520 Ramonville-St-Agne, France</json:string></affiliations></json:item><json:item><name>Karim Ioualalen</name><affiliations><json:string>A&S Biovecteurs, Parc Technologique du Canal, 10 av. de l'Europe, 31520 Ramonville-St-Agne, France</json:string></affiliations></json:item><json:item><name>Otto Merten</name><affiliations><json:string>Laboratoire de Technologie Cellulaire, Institut Pasteur, Paris, France</json:string></affiliations></json:item><json:item><name>Claude Leclerc</name><affiliations><json:string>Unité de Biologie des Régulations Immunitaires, Institut Pasteur, Paris, France</json:string></affiliations></json:item><json:item><name>Daniel Samain</name><affiliations><json:string>A&S Biovecteurs, Parc Technologique du Canal, 10 av. de l'Europe, 31520 Ramonville-St-Agne, France</json:string></affiliations></json:item><json:item><name>Pierre Perrin</name><affiliations><json:string>Lyssavirus Laboratory, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France</json:string><json:string>To whom correspondence should be addressed.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Acylated polymerized polysaccharides</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>interleukin-2</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>biological activity</value></json:item></subject><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Human recombinant interleukin-2 can be associated and released from supramolecular biovectors (SMBVs), consisting of particles made of polymerized polysaccharides. The particles are substituted with phosphate residues and contain bound lipid molecules (palmitic acid) buried near their surfaces. The association of IL-2 with SMBVs modifies its in vitro bioactivity. SMBVs prolong the growth of IL-2-dependent cells, enhance IL-2 proliferative activity and restore the activity of impaired IL-2. These properties mainly depend on the presence of lipids linked to the SMBV and on both the degree of acylation and the SMBV:IL-2 ratio. SMBVs are therefore good candidates for the stabilization and enhancement of the biological activity of IL-2.</abstract><qualityIndicators><score>6.054</score><pdfVersion>1.2</pdfVersion><pdfPageSize>591 x 843 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>741</abstractCharCount><pdfWordCount>4782</pdfWordCount><pdfCharCount>29102</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>106</abstractWordCount></qualityIndicators><title>Stabilization and enhancement of interleukin-2 in vitro bioactivity by new carriers: supramolecular biovectors</title><pii><json:string>0264-410X(94)90150-3</json:string></pii><refBibs><json:item><author><json:item><name>W. Kuziel</name></json:item><json:item><name>W. Greene</name></json:item></author><host><pages><first>83</first></pages><author></author><title>The Cytokine Handbook</title></host><title>Interleukin-2</title></json:item><json:item><author><json:item><name>K. Smith</name></json:item></author><host><volume>240</volume><pages><first>1169</first></pages><author></author><title>Science</title></host><title>Interleukin-2: inception, impact, and implications</title></json:item><json:item><author><json:item><name>A. Heath</name></json:item><json:item><name>J. Playfair</name></json:item></author><host><pages><first>215</first></pages><author></author><title>Interleukin-2</title></host><title>Vaccination and infection</title></json:item><json:item><author><json:item><name>G. Kaplan</name></json:item><json:item><name>Z. Cohn</name></json:item><json:item><name>K. Smith</name></json:item></author><host><volume>10</volume><pages><first>157</first></pages><author></author><title>Biotechnology</title></host><title>Rational immunotherapy with interleukin 2</title></json:item><json:item><author><json:item><name>M. Lotze</name></json:item><json:item><name>S. Rosenberg</name></json:item></author><host><pages><first>237</first></pages><author></author><title>Interleukin 2</title></host><title>Interleukin-2 as a pharmacologic reagent</title></json:item><json:item><author><json:item><name>S. Rosenberg</name></json:item></author><host><volume>108</volume><pages><first>853</first></pages><author></author><title>Ann. Intern. Med.</title></host><title>New approaches to the immunotherapy of cancer using interleukin-2</title></json:item><json:item><author><json:item><name>G. Anderson</name></json:item><json:item><name>O. Urban</name></json:item><json:item><name>P. Fedorka-Cray</name></json:item><json:item><name>A. Newell</name></json:item><json:item><name>J. Nunberg</name></json:item></author><host><pages><first>22</first></pages><author></author><title>Vaccines 87: Modern Approaches to New Vaccines</title></host><title>Interleukin-2 and protective immunity in Haemophilus pleuropneumoniae: preliminary studies</title></json:item><json:item><author><json:item><name>M. Haak-Frendscho</name></json:item><json:item><name>K. Young</name></json:item><json:item><name>C. Czuprynski</name></json:item></author><host><volume>57</volume><pages><first>3014</first></pages><author></author><title>Infect. Immun.</title></host><title>Treatment of mice with human recombinant interleukin-2 augments resistance to facultative intracellular pathogen Listeria monocytogenes</title></json:item><json:item><author><json:item><name>C. Weyland</name></json:item><json:item><name>J. Goronzy</name></json:item><json:item><name>G. Fathman</name></json:item><json:item><name>P. Hanley</name></json:item></author><host><volume>9</volume><pages><first>1756</first></pages><author></author><title>J. Clin. Invest.</title></host><title>Administration in vivo of recombinant interleukin-2 protects against septic death</title></json:item><json:item><author><json:item><name>P. Perrin</name></json:item><json:item><name>M.-L. Joffret</name></json:item><json:item><name>C. Leclerc</name></json:item><json:item><name>D. Oth</name></json:item><json:item><name>P. Sureau</name></json:item><json:item><name>L. Thibodeau</name></json:item></author><host><volume>177</volume><pages><first>199</first></pages><author></author><title>Immunobiology</title></host><title>Interleukin-2 increases protection against experimental rabies</title></json:item><json:item><author><json:item><name>A. Weinberg</name></json:item><json:item><name>M. Konrad</name></json:item><json:item><name>T. Merigan</name></json:item></author><host><volume>61</volume><pages><first>2120</first></pages><author></author><title>J. Virol.</title></host><title>Regulation by recombinant interleukin-2 of protective immunity against recurrent herpes simplex virus type 2 genital infection in guinea pigs</title></json:item><json:item><author><json:item><name>M. Resnick</name></json:item><json:item><name>N. Roguel</name></json:item><json:item><name>H. Bercovier</name></json:item><json:item><name>S. Enk</name></json:item><json:item><name>S. Frankenberg</name></json:item><json:item><name>E. Kedar</name></json:item></author><host><volume>113</volume><pages><first>214</first></pages><author></author><title>Cell. Immunol.</title></host><title>Lysis of murine macrophages infected with intracellular pathogens by interleukin-2 activated killer (LAK) cells in vitro</title></json:item><json:item><author><json:item><name>P. Tan</name></json:item><json:item><name>R. Booth</name></json:item><json:item><name>R. Prestidge</name></json:item><json:item><name>J. Watson</name></json:item><json:item><name>S. Dower</name></json:item><json:item><name>S. Gillis</name></json:item></author><host><author></author><title>J. Immunol.</title></host><serie><author></author><title>I. Role of interleukin-2</title></serie><title>Induction of antibody responses to influenza virus in human lymphocyte cultures</title></json:item><json:item><author><json:item><name>J. Nunberg</name></json:item><json:item><name>M. Doyle</name></json:item><json:item><name>S. York</name></json:item><json:item><name>C. York</name></json:item></author><host><author></author><title>Proc. Natl Acad. Sci. USA</title></host><serie><author></author><title>Proc. Natl Acad. Sci. USA</title></serie><title>Interleukin-2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine</title></json:item><json:item><author><json:item><name>V. Schijns</name></json:item><json:item><name>I. Claassen</name></json:item><json:item><name>A. Vermeulen</name></json:item><json:item><name>M. Horzinek</name></json:item><json:item><name>A. Osterhaus</name></json:item></author><host><volume>75</volume><pages><first>55</first></pages><author></author><title>J. Gen. Virol.</title></host><title>Modulation of antiviral immune responses by exogenous cytokines</title></json:item><json:item><author><json:item><name>A. Weinberg</name></json:item><json:item><name>T. Merigan</name></json:item></author><host><author></author><title>J. Immunol.</title></host><serie><author></author><title>Immunization of guinea pigs with herpes simplex virus subunit vaccines</title></serie><title>Recombinant interleukin-2 as an adjuvant for vaccine-induced protection</title></json:item><json:item><author><json:item><name>S. Meuer</name></json:item><json:item><name>H. Dumann</name></json:item><json:item><name>K. Meyer</name></json:item><json:item><name>H. Kohler</name></json:item></author><host><volume>i</volume><pages><first>15</first></pages><author></author><title>Lancet</title></host><title>Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficiency non-responders to hepatitis B vaccination</title></json:item><json:item><author><json:item><name>N. Katre</name></json:item><json:item><name>M. Knauf</name></json:item><json:item><name>W. Laird</name></json:item></author><host><author></author><title>Proc. Natl Acad. Sci. USA</title></host><serie><author></author><title>Proc. Natl Acad. Sci. USA</title></serie><title>Chemical modification of recombinant interleukin-2 by polyethylene glycol increases its potency in murine Meth A sarcoma model</title></json:item><json:item><author><json:item><name>P. Anderson</name></json:item><json:item><name>D. Hasz</name></json:item><json:item><name>L. Dickrell</name></json:item><json:item><name>S. Sencer</name></json:item></author><host><volume>27</volume><pages><last>31</last><first>15</first></pages><author></author><title>Drug Dev. Res.</title></host><title>Interleukin-2 in liposomes: increased intravenous potency and less pulmonary toxicity in the rat</title></json:item><json:item><author><json:item><name>W. West</name></json:item><json:item><name>K. Tauer</name></json:item><json:item><name>J. Yanelli</name></json:item></author><host><volume>316</volume><pages><first>898</first></pages><author></author><title>N. Engl. J. Med.</title></host><title>Constant infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer</title></json:item><json:item><author><json:item><name>D Parkinson</name></json:item><json:item><name>R. Fisher</name></json:item><json:item><name>A. Rayner</name></json:item></author><host><volume>8</volume><pages><first>1630</first></pages><author></author><title>J. Clin. Oncol.</title></host><title>Therapy of renal cell cancer carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with hybrid bolus and continuous infusion interleukin-2 regimen</title></json:item><json:item><author><json:item><name>P. Anderson</name></json:item><json:item><name>E. Katnasis</name></json:item><json:item><name>A. Leonard</name></json:item></author><host><volume>50</volume><pages><first>1853</first></pages><author></author><title>Cancer Res.</title></host><title>Increased local antitumor effects of interleukin-2 liposomes in mice with MCA-1076 sarcoma pulmonary metastases</title></json:item><json:item><author><json:item><name>H. Konno</name></json:item><json:item><name>A. Yamashima</name></json:item><json:item><name>T. Tadakuma</name></json:item></author><host><volume>3</volume><pages><first>211</first></pages><author></author><title>Biotherapy</title></host><title>Inhibition of growth of rat hepatoma by local injection of liposomes containing recombinant interleukin-2</title></json:item><json:item><author><json:item><name>H. Hora</name></json:item></author><host><volume>8</volume><pages><first>755</first></pages><author></author><title>Biotechnology</title></host><title>Controlled release of interleukin-2 from biodegradable microspheres</title></json:item><json:item><author><json:item><name>M.L. Joffret</name></json:item><json:item><name>C. Zanetti</name></json:item><json:item><name>S. Morgeaux</name></json:item><json:item><name>C. Leclerc</name></json:item><json:item><name>P. Sureau</name></json:item><json:item><name>P. Perrin</name></json:item></author><host><volume>19</volume><pages><first>113</first></pages><author></author><title>Biologicals</title></host><title>Appraisal of rabies vaccine potency by determination of in vitro specific Interleukin-2 production</title></json:item><json:item><host><author></author></host></json:item><json:item><author><json:item><name>P. Ferrara</name></json:item><json:item><name>F. Pecceu</name></json:item><json:item><name>E. Marchese</name></json:item><json:item><name>N. Vita</name></json:item><json:item><name>W. Riskam</name></json:item><json:item><name>J. Lupker</name></json:item></author><host><volume>226</volume><pages><first>47</first></pages><author></author><title>FEBS Lett.</title></host><title>Characterization of recombinant glycosylated human interleukin-2 produced by a recombinant plasmid transformed CHO cell line</title></json:item><json:item><author><json:item><name>S. Gillis</name></json:item><json:item><name>M. Ferm</name></json:item><json:item><name>W. Ou</name></json:item><json:item><name>K. Smith</name></json:item></author><host><volume>120</volume><pages><first>2027</first></pages><author></author><title>J. Immunol.</title></host><title>T cell growth factor: parameters of production and a quantitative microassay for activity</title></json:item><json:item><author><json:item><name>T. Mosmann</name></json:item></author><host><volume>65</volume><pages><first>55</first></pages><author></author><title>J. Immunol. Methods</title></host><title>Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays</title></json:item><json:item><author><json:item><name>A. Gearing</name></json:item><json:item><name>R. Thorpe</name></json:item></author><host><volume>114</volume><pages><first>3</first></pages><author></author><title>J. Immunol. Methods</title></host><title>The international standard for human interleukin-2: calibration by international collaborative study</title></json:item><json:item><author><json:item><name>R. Robb</name></json:item><json:item><name>K. Smith</name></json:item></author><host><volume>18</volume><pages><first>1087</first></pages><author></author><title>Mol. Immunol.</title></host><title>Heterogeneity of human T-cell growth factor(s) due to a variable glycosylation</title></json:item><json:item><author><json:item><name>D. Cantrell</name></json:item><json:item><name>K. Smith</name></json:item></author><host><volume>224</volume><pages><first>1312</first></pages><author></author><title>Science</title></host><title>The interleukin-2 T-cell system: a new cell growth model</title></json:item><json:item><author><json:item><name>D. Kaplan</name></json:item></author><host><volume>28</volume><pages><first>1255</first></pages><author></author><title>Mol. Immunol.</title></host><title>Solid phase interleukin-2</title></json:item><json:item><author><json:item><name>J. Horwitz</name></json:item><json:item><name>M. Toner</name></json:item><json:item><name>R. Tompkins</name></json:item><json:item><name>M. Yarmush</name></json:item></author><host><volume>30</volume><pages><first>1041</first></pages><author></author><title>Mol. Immunol.</title></host><title>Immobilized IL-2 preserves the viability of an IL-2 dependent cell line</title></json:item><json:item><author><json:item><name>M.-L. Joffret</name></json:item><json:item><name>S. Morgeaux</name></json:item><json:item><name>C. Leclerc</name></json:item><json:item><name>D. Oth</name></json:item><json:item><name>C. Zanetti</name></json:item><json:item><name>P. Sureau</name></json:item><json:item><name>P. Perrin</name></json:item></author><host><volume>8</volume><pages><first>385</first></pages><author></author><title>Vaccine</title></host><title>Enhancement of interleukin-2 activity by liposomes</title></json:item></refBibs><genre><json:string>research-article</json:string></genre><serie><pages><first>2128</first></pages><language><json:string>unknown</json:string></language><title>I. Role of interleukin-2</title></serie><host><volume>12</volume><pii><json:string>S0264-410X(00)X0230-7</json:string></pii><pages><last>1418</last><first>1413</first></pages><issn><json:string>0264-410X</json:string></issn><issue>15</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><title>Vaccine</title><publicationDate>1994</publicationDate></host><categories><wos><json:string>science</json:string><json:string>medicine, research & experimental</json:string><json:string>immunology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>biomedical research</json:string><json:string>virology</json:string></scienceMetrix></categories><publicationDate>1994</publicationDate><copyrightDate>1994</copyrightDate><doi><json:string>10.1016/0264-410X(94)90150-3</json:string></doi><id>5770F2CF470F8D8FABA7A3BDBE06220D55087837</id><score>0.14502099</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/5770F2CF470F8D8FABA7A3BDBE06220D55087837/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/5770F2CF470F8D8FABA7A3BDBE06220D55087837/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/5770F2CF470F8D8FABA7A3BDBE06220D55087837/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Stabilization and enhancement of interleukin-2 in vitro bioactivity by new carriers: supramolecular biovectors</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1994</date></publicationStmt><notesStmt><note type="content">Section title: Paper</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Stabilization and enhancement of interleukin-2 in vitro bioactivity by new carriers: supramolecular biovectors</title><author xml:id="author-1"><persName><forename type="first">Nathalie</forename><surname>Castignolles</surname></persName><affiliation>Lyssavirus Laboratory, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France</affiliation></author><author xml:id="author-2"><persName><forename type="first">Didier</forename><surname>Betbeder</surname></persName><affiliation>A&S Biovecteurs, Parc Technologique du Canal, 10 av. de l'Europe, 31520 Ramonville-St-Agne, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">Karim</forename><surname>Ioualalen</surname></persName><affiliation>A&S Biovecteurs, Parc Technologique du Canal, 10 av. de l'Europe, 31520 Ramonville-St-Agne, France</affiliation></author><author xml:id="author-4"><persName><forename type="first">Otto</forename><surname>Merten</surname></persName><affiliation>Laboratoire de Technologie Cellulaire, Institut Pasteur, Paris, France</affiliation></author><author xml:id="author-5"><persName><forename type="first">Claude</forename><surname>Leclerc</surname></persName><affiliation>Unité de Biologie des Régulations Immunitaires, Institut Pasteur, Paris, France</affiliation></author><author xml:id="author-6"><persName><forename type="first">Daniel</forename><surname>Samain</surname></persName><affiliation>A&S Biovecteurs, Parc Technologique du Canal, 10 av. de l'Europe, 31520 Ramonville-St-Agne, France</affiliation></author><author xml:id="author-7"><persName><forename type="first">Pierre</forename><surname>Perrin</surname></persName><affiliation>Lyssavirus Laboratory, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France</affiliation><affiliation>To whom correspondence should be addressed.</affiliation></author></analytic><monogr><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="pISSN">0264-410X</idno><idno type="PII">S0264-410X(00)X0230-7</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1994"></date><biblScope unit="volume">12</biblScope><biblScope unit="issue">15</biblScope><biblScope unit="page" from="1413">1413</biblScope><biblScope unit="page" to="1418">1418</biblScope></imprint></monogr><idno type="istex">5770F2CF470F8D8FABA7A3BDBE06220D55087837</idno><idno type="DOI">10.1016/0264-410X(94)90150-3</idno><idno type="PII">0264-410X(94)90150-3</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1994</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Human recombinant interleukin-2 can be associated and released from supramolecular biovectors (SMBVs), consisting of particles made of polymerized polysaccharides. The particles are substituted with phosphate residues and contain bound lipid molecules (palmitic acid) buried near their surfaces. The association of IL-2 with SMBVs modifies its in vitro bioactivity. SMBVs prolong the growth of IL-2-dependent cells, enhance IL-2 proliferative activity and restore the activity of impaired IL-2. These properties mainly depend on the presence of lipids linked to the SMBV and on both the degree of acylation and the SMBV:IL-2 ratio. SMBVs are therefore good candidates for the stabilization and enhancement of the biological activity of IL-2.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>Acylated polymerized polysaccharides</term></item><item><term>interleukin-2</term></item><item><term>biological activity</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1993-12-16">Modified</change><change when="1994">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/5770F2CF470F8D8FABA7A3BDBE06220D55087837/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>JVAC</jid><aid>94901503</aid><ce:pii>0264-410X(94)90150-3</ce:pii><ce:doi>10.1016/0264-410X(94)90150-3</ce:doi><ce:copyright type="unknown" year="1994"></ce:copyright></item-info><head><ce:dochead><ce:textfn>Paper</ce:textfn></ce:dochead><ce:title>Stabilization and enhancement of interleukin-2 <ce:italic>in vitro</ce:italic> bioactivity by new carriers: supramolecular biovectors</ce:title><ce:author-group><ce:author><ce:given-name>Nathalie</ce:given-name><ce:surname>Castignolles</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Didier</ce:given-name><ce:surname>Betbeder</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>†</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Karim</ce:given-name><ce:surname>Ioualalen</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>†</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Otto</ce:given-name><ce:surname>Merten</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>‡</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Claude</ce:given-name><ce:surname>Leclerc</ce:surname><ce:cross-ref refid="AFF4"><ce:sup>∞</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Daniel</ce:given-name><ce:surname>Samain</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>†</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Pierre</ce:given-name><ce:surname>Perrin</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref><ce:cross-ref refid="COR1"><ce:sup>|</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>∗</ce:label><ce:textfn>Lyssavirus Laboratory, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>†</ce:label><ce:textfn>A&S Biovecteurs, Parc Technologique du Canal, 10 av. de l'Europe, 31520 Ramonville-St-Agne, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF3"><ce:label>‡</ce:label><ce:textfn>Laboratoire de Technologie Cellulaire, Institut Pasteur, Paris, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF4"><ce:label>∞</ce:label><ce:textfn>Unité de Biologie des Régulations Immunitaires, Institut Pasteur, Paris, France</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>|</ce:label><ce:text>To whom correspondence should be addressed.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="16" month="8" year="1993"></ce:date-received><ce:date-revised day="16" month="12" year="1993"></ce:date-revised><ce:date-accepted day="5" month="4" year="1994"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Human recombinant interleukin-2 can be associated and released from supramolecular biovectors (SMBVs), consisting of particles made of polymerized polysaccharides. The particles are substituted with phosphate residues and contain bound lipid molecules (palmitic acid) buried near their surfaces. The association of IL-2 with SMBVs modifies its <ce:italic>in vitro</ce:italic> bioactivity. SMBVs prolong the growth of IL-2-dependent cells, enhance IL-2 proliferative activity and restore the activity of impaired IL-2. These properties mainly depend on the presence of lipids linked to the SMBV and on both the degree of acylation and the SMBV:IL-2 ratio. SMBVs are therefore good candidates for the stabilization and enhancement of the biological activity of IL-2.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Acylated polymerized polysaccharides</ce:text></ce:keyword><ce:keyword><ce:text>interleukin-2</ce:text></ce:keyword><ce:keyword><ce:text>biological activity</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Stabilization and enhancement of interleukin-2 in vitro bioactivity by new carriers: supramolecular biovectors</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Stabilization and enhancement of interleukin-2</title></titleInfo><name type="personal"><namePart type="given">Nathalie</namePart><namePart type="family">Castignolles</namePart><affiliation>Lyssavirus Laboratory, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Didier</namePart><namePart type="family">Betbeder</namePart><affiliation>A&S Biovecteurs, Parc Technologique du Canal, 10 av. de l'Europe, 31520 Ramonville-St-Agne, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Karim</namePart><namePart type="family">Ioualalen</namePart><affiliation>A&S Biovecteurs, Parc Technologique du Canal, 10 av. de l'Europe, 31520 Ramonville-St-Agne, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Otto</namePart><namePart type="family">Merten</namePart><affiliation>Laboratoire de Technologie Cellulaire, Institut Pasteur, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Claude</namePart><namePart type="family">Leclerc</namePart><affiliation>Unité de Biologie des Régulations Immunitaires, Institut Pasteur, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Daniel</namePart><namePart type="family">Samain</namePart><affiliation>A&S Biovecteurs, Parc Technologique du Canal, 10 av. de l'Europe, 31520 Ramonville-St-Agne, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pierre</namePart><namePart type="family">Perrin</namePart><affiliation>Lyssavirus Laboratory, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France</affiliation><affiliation>To whom correspondence should be addressed.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1994</dateIssued><dateModified encoding="w3cdtf">1993-12-16</dateModified><copyrightDate encoding="w3cdtf">1994</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Human recombinant interleukin-2 can be associated and released from supramolecular biovectors (SMBVs), consisting of particles made of polymerized polysaccharides. The particles are substituted with phosphate residues and contain bound lipid molecules (palmitic acid) buried near their surfaces. The association of IL-2 with SMBVs modifies its in vitro bioactivity. SMBVs prolong the growth of IL-2-dependent cells, enhance IL-2 proliferative activity and restore the activity of impaired IL-2. These properties mainly depend on the presence of lipids linked to the SMBV and on both the degree of acylation and the SMBV:IL-2 ratio. SMBVs are therefore good candidates for the stabilization and enhancement of the biological activity of IL-2.</abstract><note type="content">Section title: Paper</note><subject><genre>Keywords</genre><topic>Acylated polymerized polysaccharides</topic><topic>interleukin-2</topic><topic>biological activity</topic></subject><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><titleInfo type="abbreviated"><title>JVAC</title></titleInfo><genre type="journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">1994</dateIssued></originInfo><identifier type="ISSN">0264-410X</identifier><identifier type="PII">S0264-410X(00)X0230-7</identifier><part><date>1994</date><detail type="volume"><number>12</number><caption>vol.</caption></detail><detail type="issue"><number>15</number><caption>no.</caption></detail><extent unit="issue pages"><start>1363</start><end>1488</end></extent><extent unit="pages"><start>1413</start><end>1418</end></extent></part></relatedItem><identifier type="istex">5770F2CF470F8D8FABA7A3BDBE06220D55087837</identifier><identifier type="DOI">10.1016/0264-410X(94)90150-3</identifier><identifier type="PII">0264-410X(94)90150-3</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F12 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000F12 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:5770F2CF470F8D8FABA7A3BDBE06220D55087837
|texte= Stabilization and enhancement of interleukin-2 in vitro bioactivity by new carriers: supramolecular biovectors
}}
| This area was generated with Dilib version V0.6.29. |  |